نتایج جستجو برای: bev

تعداد نتایج: 754  

2015
Alexander Kumachev Marie Yan Scott Berry Yoo-Joung Ko Maria C. R. Martinez Keya Shah Kelvin K. W. Chan Daniele Santini

BACKGROUND Epithelial growth factor receptor inhibitors (EGFRis) and bevacizumab (BEV) are used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). However, few randomized controlled trials (RCTs) have directly compared their relative efficacy on progression-free survival (PFS) and overall survival (OS). METHODS We conducted a systematic review of first-...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2015
C Cremolini F Loupakis C Antoniotti S Lonardi G Masi L Salvatore E Cortesi G Tomasello R Spadi A Zaniboni G Tonini C Barone S Vitello R Longarini A Bonetti M D'Amico S Di Donato C Granetto L Boni A Falcone

BACKGROUND Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOL...

2016
Hidetaka Uramoto Yuki Nakajima Hiroyasu Kinoshita

Recent new drugs, such as bevacizumab (Bev), also result in a remarkable response. However, the safety of major lung resection after the use of Bev remains controversial. Is it really dangerous to perform major lung resection after the use of Bev for a lung tumor? In this report, we describe two patients who underwent surgery safely without fragile pathological findings of the vessels.

2015
Lisa B. E. Shields Brent J. Shelton Andrew J. Shearer Li Chen David A. Sun Sarah Parsons T. David Bourne Renato LaRocca Aaron C. Spalding

BACKGROUND Dexamethasone (DXM) is commonly used in the management of cerebral edema in patients diagnosed with glioblastoma multiforme (GBM). Bevacizumab (BEV) is FDA-approved for the progression or recurrence of GBM but has not been shown to improve survival when given for newly diagnosed patients concurrently with radiation (RT) and temozolomide (TMZ). Both DXM and BEV reduce cerebral edema, ...

2017
Alessia E Russo Domenico Priolo Giovanna Antonelli Massimo Libra James A McCubrey Francesco Ferraù

Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial gro...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011
N E Kemeny L H Schwartz M Gonen A C Yopp M I D'Angelica Y Fong D Haviland A N Gewirtz P J Allen W R Jarnagin

e14658 Background: Unresectable primary liver cancer (UPLC), including intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC), has poor median survival, typically 10 to 11 months. Hepatic arterial infusion (HAI) has previously shown efficacy, and adding bevacizumab (Bev) may induce changes in the tumor vasculature that improve local delivery of HAI. METHODS Patients with UPL...

2018
Jennifer Jeck Rebecca Kassubek Jan Coburger Simone Edenhofer Stefan S. Schönsteiner Albert C. Ludolph Bernd Schmitz Jens Engelke Regine Mayer-Steinacker Jan Lewerenz Lars Bullinger

Background Despite multidisciplinary treatment approaches, the prognosis for patients with high-grade glioma (HGG) is poor, with a median overall survival (OS) of 14.6 months for glioblastoma multiforme (GB). As high levels of vascular endothelial growth factor A (VEGF) are found in HGG, targeted anti-antiangiogenic therapy using the humanized monoclonal antibody bevacizumab (BEV) was studied i...

Journal: :Molecular cancer therapeutics 2014
Niranjan Awasthi Changhua Zhang Anna M Schwarz Stefan Hinz Margaret A Schwarz Roderich E Schwarz

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, NPT) has recently shown efficacy in pancreatic ductal adenocarcinoma (PDAC). Targeting tumor angiogenesis is a sensible combination therapeutic strategy for cancer, including PDAC. We tested the hypothesis that NPT response in PDAC can be enhanced by the mechanistically different antiangiogenic agents bevacizumab (Bev) or sunitinib (Su), de...

2012
Jeevan Kumar Manorama Bhargava Shyam Aggarwal

We report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) regimen along with BEV 10 mg/kg for 6 cycles. After that, BEV was...

2015
Z. LI M. CHOWDHURY P. BHAVSAR

−A smart charge scheduling model is presented for potential (1) vehicle-to-grid (V2G) enabled battery electric vehicle (BEV) owners who are willing to participate in the grid ancillary services, and (2) grid operators. Unlike most V2G implementations, which are considered from the perspective of power grid systems, this model includes a communication network architecture for connecting system c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید